Related Experiment Video
Updated: Aug 21, 2026

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
Published on: June 18, 2018
Bupropion SR for relapse prevention: a "slips-allowed" analysis
Michael J Durcan1, J Andrew Johnston, Jonathan White
1Smoking Control, GlaxoSmithKline, 1500 Littleton Road, Parsippany, NJ 07054, USA. Michael.J.Durcan@GSK.com
Objective:
To assess the efficacy of bupropion SR on smoking abstinence using a "slips allowed" analysis.
Methods:
Retrospective analysis, which did not consider brief episodic "slips" as a return to regular smoking, of data from a multicenter, randomized, doubleblind, placebo-controlled relapse prevention study.
Results:
Using a slips-allowed analysis, median time to relapse on bupropion SR was 65 weeks versus 30 weeks on placebo. This is compared to 32 and 20 weeks, respectively, using a traditional analysis not allowing for slips.
Conclusion:
Bupropion SR is efficacious for the prevention of smoking relapse. A slips-allowed analysis may provide a more clinically relevant assessment of efficacy.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Oral Drug Delivery Systems: Continuous-Release Systems
Drug Dependence
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...